486 related articles for article (PubMed ID: 35346215)
1. Clinical significance of FBXW7 loss of function in human cancers.
Fan J; Bellon M; Ju M; Zhao L; Wei M; Fu L; Nicot C
Mol Cancer; 2022 Mar; 21(1):87. PubMed ID: 35346215
[TBL] [Abstract][Full Text] [Related]
2. FBXW7: a critical tumor suppressor of human cancers.
Yeh CH; Bellon M; Nicot C
Mol Cancer; 2018 Aug; 17(1):115. PubMed ID: 30086763
[TBL] [Abstract][Full Text] [Related]
3. Recent insight into the role of FBXW7 as a tumor suppressor.
Yumimoto K; Nakayama KI
Semin Cancer Biol; 2020 Dec; 67(Pt 2):1-15. PubMed ID: 32113998
[TBL] [Abstract][Full Text] [Related]
4. The FBXW7-NOTCH interactome: A ubiquitin proteasomal system-induced crosstalk modulating oncogenic transformation in human tissues.
Kar R; Jha SK; Ojha S; Sharma A; Dholpuria S; Raju VSR; Prasher P; Chellappan DK; Gupta G; Kumar Singh S; Paudel KR; Hansbro PM; Kumar Singh S; Ruokolainen J; Kesari KK; Dua K; Jha NK
Cancer Rep (Hoboken); 2021 Aug; 4(4):e1369. PubMed ID: 33822486
[TBL] [Abstract][Full Text] [Related]
5. The Role of FBXW7 in Gynecologic Malignancies.
Di Fiore R; Suleiman S; Drago-Ferrante R; Subbannayya Y; Suleiman S; Vasileva-Slaveva M; Yordanov A; Pentimalli F; Giordano A; Calleja-Agius J
Cells; 2023 May; 12(10):. PubMed ID: 37408248
[TBL] [Abstract][Full Text] [Related]
6. Loss of Fbxw7 triggers mammary tumorigenesis associated with E2F/c-Myc activation and Trp53 mutation.
Meyer AE; Furumo Q; Stelloh C; Minella AC; Rao S
Neoplasia; 2020 Nov; 22(11):644-658. PubMed ID: 33070870
[TBL] [Abstract][Full Text] [Related]
7. FBXW7/hCDC4 is a general tumor suppressor in human cancer.
Akhoondi S; Sun D; von der Lehr N; Apostolidou S; Klotz K; Maljukova A; Cepeda D; Fiegl H; Dafou D; Marth C; Mueller-Holzner E; Corcoran M; Dagnell M; Nejad SZ; Nayer BN; Zali MR; Hansson J; Egyhazi S; Petersson F; Sangfelt P; Nordgren H; Grander D; Reed SI; Widschwendter M; Sangfelt O; Spruck C
Cancer Res; 2007 Oct; 67(19):9006-12. PubMed ID: 17909001
[TBL] [Abstract][Full Text] [Related]
8. The Highs and Lows of FBXW7: New Insights into Substrate Affinity in Disease and Development.
de la Cova CC
Cells; 2023 Aug; 12(17):. PubMed ID: 37681873
[TBL] [Abstract][Full Text] [Related]
9. SCF(FBXW7)-mediated degradation of p53 promotes cell recovery after UV-induced DNA damage.
Galindo-Moreno M; Giráldez S; Limón-Mortés MC; Belmonte-Fernández A; Reed SI; Sáez C; Japón MÁ; Tortolero M; Romero F
FASEB J; 2019 Oct; 33(10):11420-11430. PubMed ID: 31337255
[TBL] [Abstract][Full Text] [Related]
10. The WD40 domain of FBXW7 is a poly(ADP-ribose)-binding domain that mediates the early DNA damage response.
Zhang Q; Mady ASA; Ma Y; Ryan C; Lawrence TS; Nikolovska-Coleska Z; Sun Y; Morgan MA
Nucleic Acids Res; 2019 May; 47(8):4039-4053. PubMed ID: 30722038
[TBL] [Abstract][Full Text] [Related]
11. In vitro effects of FBXW7 mutation in serous endometrial cancer: Increased levels of potentially druggable proteins and sensitivity to SI-2 and dinaciclib.
Urick ME; Bell DW
Mol Carcinog; 2018 Nov; 57(11):1445-1457. PubMed ID: 29963728
[TBL] [Abstract][Full Text] [Related]
12. Recombinant human adenovirus-p53 injection induced apoptosis in hepatocellular carcinoma cell lines mediated by p53-Fbxw7 pathway, which controls c-Myc and cyclin E.
Tu K; Zheng X; Zhou Z; Li C; Zhang J; Gao J; Yao Y; Liu Q
PLoS One; 2013; 8(7):e68574. PubMed ID: 23840897
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA-223 regulates cyclin E activity by modulating expression of F-box and WD-40 domain protein 7.
Xu Y; Sengupta T; Kukreja L; Minella AC
J Biol Chem; 2010 Nov; 285(45):34439-46. PubMed ID: 20826802
[TBL] [Abstract][Full Text] [Related]
14. Loss of FBXW7 and accumulation of MCL1 and PLK1 promote paclitaxel resistance in breast cancer.
Gasca J; Flores ML; Giráldez S; Ruiz-Borrego M; Tortolero M; Romero F; Japón MA; Sáez C
Oncotarget; 2016 Aug; 7(33):52751-52765. PubMed ID: 27409838
[TBL] [Abstract][Full Text] [Related]
15. FBXW7 tumor suppressor regulation by dualspecificity tyrosine-regulated kinase 2.
Jiménez-Izquierdo R; Morrugares R; Suanes-Cobos L; Correa-Sáez A; Garrido-Rodríguez M; Cerero-Tejero L; Khan OM; de la Luna S; Sancho R; Calzado MA
Cell Death Dis; 2023 Mar; 14(3):202. PubMed ID: 36934104
[TBL] [Abstract][Full Text] [Related]
16. The Fbxw7/hCdc4 tumor suppressor in human cancer.
Tan Y; Sangfelt O; Spruck C
Cancer Lett; 2008 Nov; 271(1):1-12. PubMed ID: 18541364
[TBL] [Abstract][Full Text] [Related]
17. Loss of FBXW7-mediated degradation of BRAF elicits resistance to BET inhibitors in adult T cell leukemia cells.
Yeh CH; Bellon M; Wang F; Zhang H; Fu L; Nicot C
Mol Cancer; 2020 Sep; 19(1):139. PubMed ID: 32907612
[TBL] [Abstract][Full Text] [Related]
18. FBXW7-mediated ERK3 degradation regulates the proliferation of lung cancer cells.
An HJ; Lee CJ; Lee GE; Choi Y; Jeung D; Chen W; Lee HS; Kang HC; Lee JY; Kim DJ; Choi JS; Cho ES; Choi JS; Cho YY
Exp Mol Med; 2022 Jan; 54(1):35-46. PubMed ID: 35022544
[TBL] [Abstract][Full Text] [Related]
19. SCF
O'Brien S; Kelso S; Steinhart Z; Orlicky S; Mis M; Kim Y; Lin S; Sicheri F; Angers S
EMBO Rep; 2022 Dec; 23(12):e55044. PubMed ID: 36278408
[TBL] [Abstract][Full Text] [Related]
20. FBXW7 influences murine intestinal homeostasis and cancer, targeting Notch, Jun, and DEK for degradation.
Babaei-Jadidi R; Li N; Saadeddin A; Spencer-Dene B; Jandke A; Muhammad B; Ibrahim EE; Muraleedharan R; Abuzinadah M; Davis H; Lewis A; Watson S; Behrens A; Tomlinson I; Nateri AS
J Exp Med; 2011 Feb; 208(2):295-312. PubMed ID: 21282377
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]